NasdaqGM:KODBiotechs
Kodiak Sciences Zenkuda Trial Win Puts Cash Needs And Growth In Focus
Kodiak Sciences (NasdaqGM:KOD) reported positive phase III results for its drug candidate Zenkuda in diabetic retinopathy.
The company is accelerating regulatory submissions following the data readout, aiming to move the program toward potential approval.
Kodiak Sciences is drawing fresh attention after this clinical update, with the stock at $34.16 and up strongly year to date, including a very large gain over the past 1 year. At the same time, shares are down 5.4% over the past week and...